CG OncologyCGON
CGON
About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Employees: 113
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
531% more call options, than puts
Call options by funds: $6.49M | Put options by funds: $1.03M
119% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 27
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
16% more funds holding
Funds holding: 121 [Q3] → 140 (+19) [Q4]
10.58% more ownership
Funds ownership: 77.79% [Q3] → 88.38% (+10.58%) [Q4]
9% more funds holding in top 10
Funds holding in top 10: 11 [Q3] → 12 (+1) [Q4]
3% less capital invested
Capital invested by funds: $1.96B [Q3] → $1.9B (-$67.1M) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
15%
downside
Avg. target
$59
120%
upside
High target
$75
178%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
RBC Capital Gregory Renza 29% 1-year accuracy 22 / 75 met price target | 152%upside $68 | Outperform Maintained | 29 Apr 2025 |
Cantor Fitzgerald Josh Schimmer 25% 1-year accuracy 14 / 55 met price target | 178%upside $75 | Overweight Reiterated | 28 Apr 2025 |
HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 15 / 53 met price target | 178%upside $75 | Buy Reiterated | 28 Apr 2025 |
Scotiabank | 15%downside $23 | Sector Perform Initiated | 16 Apr 2025 |
Morgan Stanley Jeffrey Hung 16% 1-year accuracy 4 / 25 met price target | 104%upside $55 | Overweight Assumed | 7 Mar 2025 |
Financial journalist opinion
Based on 5 articles about CGON published over the past 30 days
Positive
Zacks Investment Research
1 day ago
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Benzinga
2 days ago
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
Positive
Investors Business Daily
2 days ago
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.
Neutral
GlobeNewsWire
4 days ago
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA
Positive
Seeking Alpha
4 weeks ago
CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74.5% CR rate in the BOND-003 trial and a 41.2% CR rate in a phase 1 trial for MIBC. A basic DCF valuation estimates CGON's enterprise value at $5.3bn, suggesting a price target of $69, about 3x the current price.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Neutral
GlobeNewsWire
2 months ago
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET.
Positive
Zacks Investment Research
3 months ago
Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?
The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
4 months ago
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the closing of its public offering of 9,200,000 shares of its common stock, 8,500,000 of which were offered by CG Oncology, which includes the exercise in full by the underwriters of their option to purchase 1,200,000 additional shares, and 700,000 of which were offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share.
Charts implemented using Lightweight Charts™